ZYBERNO
Stock Report
Updated Sep 1, 2026

BioVie Inc. (BIVI)

Healthcare • NASDAQ

$2.35

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
BioVie Inc. (BIVI) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-126.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.05x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,083.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BioVie Inc. (BIVI) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.35
Market Cap:$17.03M

Valuation Multiples (2)

P/B Ratio:1.66x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.33M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (5)

ROA:-108.9%
Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-11.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$217.86
Dividend Yield:0.4%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-84.5%
Latest Earnings Filed:2026-05-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.59x
Quick Ratio:3.59x
Cash Ratio:2.37x

Leverage Analysis (3)

Debt To Equity Ttm:0.05x
Debt-to-Equity Ratio:0.05x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,265.39x
Times Interest Earned:-1,265.39

Capital Structure (4)

Working Capital:9,846,394.00
Cash And Cash Equivalents:8,977,370.00
Long Term Debt:$184.42K
Net Debt:-$8.70M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$22.65M

Bottom Line Performance (3)

-$22.07M
Income Before Tax:$0.00
Ebitda Ttm:-22,473,392.00

Operating Expenses (5)

Operating Expenses:22,651,733.00
R And D Expense:13,962,360.00
Sga Expense:8,511,032.00
Income Tax Expense:$0.00
Interest Expense:17,901.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$14.25M
Current Assets:$13.64M
Ppe Net:0.00
Goodwill:345,711.00
Intangible Assets:$6.31K

Liability Structure (4)

Total Liabilities:3,980,192.00
Current Liabilities:3,795,771.00
Long Term Debt:$184.42K
Short Term Debt:$91.01K

Equity & Capital (3)

Equity:$10.27M
Retained Earnings:-$374.26M
Common Stock:800,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,704,762.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:256,719.00
C. Cash Flow Analysis

Operating Activities (2)

-$19.02M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:43,544.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:10,457,629.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:178,341.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.05
-$3.05
Earnings Per Share Ttm:-$3.05

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.63

Book Value & Capital (2)

Book Value Per Share:$1.42
Cash Per Share:1.24

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-11.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):7.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:BIVI
Company Name:BioVie Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:7.25M
Shares Outstanding Basic:7.25M
Shares Outstanding Diluted:7.25M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:40:08 UTC
Data Timestamp:2026-08-21T12:57:21.983798
Scroll to Top